Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Royal Brisbane and Women's Hospital

Status and phase

Completed

Phase 1

Conditions

Multiple System Atrophy

Parkinson's Disease

Orthostatic Hypotension

Treatments

Behavioral: Conservative Measures for Orthostatic Hypotension

Drug: Fludrocortisone

Drug: Domperidone

Study type

Interventional

Funder types

Other

Identifiers

NCT00103597

2004/135

Details and patient eligibility

About

Patients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of orthostatic hypotension, are eligible for the study. Each patient will have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.

Full description

Enrolled patients, ages 40-95, must have Parkinson's or MSA, diagnosed by a neurologist, and symptoms of orthostatic hypotension. Each patient will fill out two validated questionnaires to determine if they are candidates for the study. Baseline patient details, such as their medications and UPDRS, will be recorded. Medications must be held stable during the period of the study.

Each patient will then have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and UPDRS will be performed after each intervention.

Sex

All

Ages

40 to 95 years old

Volunteers

No Healthy Volunteers

Inclusion criteria